Gilchrist A - Search Results

1

Pharmacological intervention at CCR1 and CCR5 as an approach for cancer: help or hindrance.

Karash A, Mazzoni MR, Gilchrist A. Karash A, et al. Among authors: gilchrist a. Curr Top Med Chem. 2014;14(13):1553-73. doi: 10.2174/1568026614666140827144440. Curr Top Med Chem. 2014. PMID: 25159162 Review.

2

Therapeutic potential of CCR1 antagonists for multiple myeloma.

Karash AR, Gilchrist A. Karash AR, et al. Among authors: gilchrist a. Future Med Chem. 2011 Nov;3(15):1889-908. doi: 10.4155/fmc.11.144. Future Med Chem. 2011. PMID: 22023033 Review.

3

Identifying bias in CCR1 antagonists using radiolabelled binding, receptor internalization, β-arrestin translocation and chemotaxis assays.

Gilchrist A, Gauntner TD, Fazzini A, Alley KM, Pyen DS, Ahn J, Ha SJ, Willett A, Sansom SE, Yarfi JL, Bachovchin KA, Mazzoni MR, Merritt JR. Gilchrist A, et al. Br J Pharmacol. 2014 Nov;171(22):5127-38. doi: 10.1111/bph.12835. Br J Pharmacol. 2014. PMID: 24990525 Free PMC article.

4

Antagonists of the receptor-G protein interface block Gi-coupled signal transduction.

Gilchrist A, Mazzoni MR, Dineen B, Dice A, Linden J, Proctor WR, Lupica CR, Dunwiddie TV, Hamm HE. Gilchrist A, et al. J Biol Chem. 1998 Jun 12;273(24):14912-9. doi: 10.1074/jbc.273.24.14912. J Biol Chem. 1998. PMID: 9614095 Free article.

5

Modulation of PAR(1) signalling by benzimidazole compounds.

Asteriti S, Daniele S, Porchia F, Dell'Anno MT, Fazzini A, Pugliesi I, Trincavelli ML, Taliani S, Martini C, Mazzoni MR, Gilchrist A. Asteriti S, et al. Among authors: gilchrist a. Br J Pharmacol. 2012 Sep;167(1):80-94. doi: 10.1111/j.1476-5381.2012.01974.x. Br J Pharmacol. 2012. PMID: 22519452 Free PMC article.

6

Targeting Chemokine Receptor CCR1 as a Potential Therapeutic Approach for Multiple Myeloma.

Gilchrist A, Echeverria SL. Gilchrist A, et al. Front Endocrinol (Lausanne). 2022 Mar 25;13:846310. doi: 10.3389/fendo.2022.846310. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 35399952 Free PMC article. Review.

7

Chemokines and Bone.

Gilchrist A. Gilchrist A. Handb Exp Pharmacol. 2020;262:231-258. doi: 10.1007/164_2020_349. Handb Exp Pharmacol. 2020. PMID: 32661663 Review.

8

Homology modeling of FFA2 identifies novel agonists that potentiate insulin secretion.

Villa SR, Mishra RK, Zapater JL, Priyadarshini M, Gilchrist A, Mancebo H, Schiltz GE, Layden BT. Villa SR, et al. Among authors: gilchrist a. J Investig Med. 2017 Dec;65(8):1116-1124. doi: 10.1136/jim-2017-000523. Epub 2017 Aug 7. J Investig Med. 2017. PMID: 28784695 Free PMC article.

9

BJCP 40th anniversary: moving forward, looking back.

Gilchrist A, Loke YK, Somogyi AA, Cohen AF, Ritter JM. Gilchrist A, et al. Br J Clin Pharmacol. 2014 Dec;78(6):1175-84. doi: 10.1111/bcp.12520. Br J Clin Pharmacol. 2014. PMID: 25410787 Free PMC article. No abstract available.

10

An Acetate-Specific GPCR, FFAR2, Regulates Insulin Secretion.

Priyadarshini M, Villa SR, Fuller M, Wicksteed B, Mackay CR, Alquier T, Poitout V, Mancebo H, Mirmira RG, Gilchrist A, Layden BT. Priyadarshini M, et al. Among authors: gilchrist a. Mol Endocrinol. 2015 Jul;29(7):1055-66. doi: 10.1210/me.2015-1007. Epub 2015 Jun 15. Mol Endocrinol. 2015. PMID: 26075576 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

334 results

Search Page